A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Public ClinicalTrials.gov record NCT01310816. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Study identification
- NCT ID
- NCT01310816
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- IPI-926 Drug
- Placebo Arm Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2011
- Primary completion
- Oct 31, 2013
- Completion
- Nov 30, 2013
- Last update posted
- Dec 4, 2013
2011 – 2013
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| (TGen) Translational Genomics Research Institute | Scottsdale | Arizona | 85258 | — |
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Pennsylvania Oncology Hematology Associates | Philadelphia | Pennsylvania | 19106 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01310816, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2013 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01310816 live on ClinicalTrials.gov.